A recently concluded study by Merck & Co. on its drug Gardasil showed extraordinary promise at preventing some types of cervical cancer.
The drug which involves technology licensed from CSL Ltd. in Australia, was the center of a study on 12,000+ women aged 16 to 26 in 13 countries all around the world.
Gardasil is targeted mainly at HumanPapillomaVirus (HPV) types 16 and 18 which are responsible for roughly 70 percent of all cervical cancers.
The Rate of Prevention of CIN 2/3 and AIS* for the women who received all 3 doses of the drug, did not violate testing protocols and didn’t develop HPV 16 or 18 by month 7 was 100%.
Even more astounding was the Prevention Rate of 97% for the 5,000+ women who received less than 3 doses, violated testing protocols, and/or developed HPV 16 or 18 before month 7.
Given the success of the Future II study, plans are in the works to get the drug FDA approved, innoculate women before the age of sexual activity and continue development for increased protection from remaining types of cervical cancer.
Photo Credits: “Freedom”, by Audrey Johnson
Merck CNN-Gardasil Yahoo-Gardasil
*Cervical-Intraepithelial-Neoplasia 2/3 & Adenocarcinoma-In-Situ